Skip to main content
. 2021 Jun 22;9(6):e002553. doi: 10.1136/jitc-2021-002553

Figure 3.

Figure 3

Ninety-day survival of patients with severe myocarditis (1), subclinical myocarditis (2), and other cardiotoxicities (3). Ninety-day survival did not significantly differ between the three groups of immune checkpoint inhibitor-associated toxicities.